Related Experiment Videos
Use of digoxin in infants and children, with specific emphasis on dosage
Insights
Pediatric patients, especially infants, require higher digoxin doses due to faster clearance and distribution, but do not need higher serum levels for therapeutic effects. Higher levels increase toxicity risk, particularly with diuretics.
Area of Science:
- Pediatric Pharmacology
- Cardiovascular Therapeutics
Background:
- Digoxin use in pediatric patients presents unique pharmacokinetic and pharmacodynamic considerations.
- Established adult dosing guidelines may not directly translate to infants and children.
Purpose of the Study:
- To elucidate the appropriate digoxin dosing and serum levels for pediatric patients.
- To clarify the relationship between serum digoxin levels, myocardial uptake, and therapeutic effects in children.
Main Methods:
- Review of pharmacokinetic studies comparing infants and adults.
- Analysis of myocardial to serum digoxin ratios in different age groups.
- Evaluation of animal studies on inotropic sensitivity in the young.
- Assessment of the correlation between high serum digoxin levels and toxicity in pediatric patients.
Main Results:
- Infants exhibit more rapid digoxin clearance and a larger volume of distribution, necessitating higher doses for equivalent serum levels.
- Myocardial uptake of digoxin is higher in infants and children than in adults.
- Younger patients may have greater inotropic sensitivity to digoxin and decreased conduction system sensitivity to toxicity.
- Serum digoxin levels above 2 ng/ml do not enhance inotropic effects but increase toxicity, especially with diuretic co-administration.
Conclusions:
- Pediatric patients, particularly infants, do not require higher serum digoxin levels for therapeutic benefit.
- Optimal digoxin dosage recommendations aim for serum levels of 1.1 to 1.7 ng/ml to balance efficacy and minimize toxicity.
- Current understanding suggests infants tolerate, rather than require, higher digoxin concentrations.
Abstract:
The foregoing discussion leads to several general conclusions regarding the use of digoxin in the pediatric patient. First, pharmacokinetic studies indicate that somewhat higher doses are required in the infant to attain the same serum levels as in the adult. Important sources for this difference appear to be more rapid body clearance of digoxin and larger volume of distribution in the infant. Second, higher serum digoxin levels are not indicated on the basis of decreased myocardial uptake of digoxin in the infant. Tissue uptake of digoxin, as indicated by myocardium/serum digoxin ratios, is higher in infants and children than in adults. Third, according to results of animal studies, the inotropic sensitivity to digoxin in the young is probably greater--certainly not less--than in the adult. This is opposite to a commonly held view that the immature heart is less sensitive to cardiac glycosides and therefore requires higher serum levels for a therapeutic effect. Rather, the infant has decreased sensitivity of the conduction system to digitalis toxicity, and healthy myocardium less prone to arrhythmia than the adult. Therefore the infant may tolerate, but does not require, higher serum levels of digoxin. Fourth, high levels of serum digoxin (greater than 2 ng/ml) are not associated with greater inotropic effects in the pediatric patient. The higher dosages of digoxin are, instead, associated with greater frequency of toxic effects, especially in infants receiving concomitant diuretic therapy. Therefore, a digoxin dosage recommendation is presented, that will result in mean serum digoxin levels of 1.1 to 1.7 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)